FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003948381> ?p ?o ?g. }

• W2003948381 endingPage "785" @default.
• W2003948381 startingPage "773" @default.
• W2003948381 abstract "Background: Topical erythromycin/benzoyl peroxide (EBP), marketed for acne treatment, must be compounded by a pharmacist and requires subsequent refrigeration, warranting the development of alternate formulations. Objective: This trial compared the efficacy and tolerability of a single-use EBP combination package (EBP Pak) with those of its matching vehicle control (VC Pak) and the original, reconstituted formulation packaged in a jar (EBP Jar). The matching VC for the original formulation (VC Jar) was used to achieve study blinding. Methods: In this double-blind, parallel-group, multicenter study, patients were randomly assigned to the 4 treatment arms. The primary efficacy evaluations were lesion reductions from baseline and treatment success (as defined by a Physician's Global Acne Severity score of 0 [clear] or 0.5 [sparse comedones with few or no inflammatory lesions]). Secondary evaluations were Physician's Global Acne Severity scores, facial-oiliness scores, and end-point patient evaluations of global improvement and treatment acceptability. Tolerability was based on the incidence and severity of adverse events. Results: Three hundred twenty-seven patients (age range, 12–46 years) were randomly assigned to the 4 treatment groups (EBP Pak, 124; VC Pak, 42; EBP Jar, 121; VC Jar, 40). Mean percent reductions in total acne lesions, inflammatory acne lesions, and come-dones from baseline were significantly greater with EBP Pak than with VC Pak (P≤0.001 for the intent-to-treat patient population after 8 weeks). Statistical significance for all lesion parameters was demonstrated at week 2 (P < 0.05) and maintained throughout the study. At 8 weeks, a significantly greater proportion of patients demonstrated treatment success with the EBP Pak compared with VC Pak (28% vs 2%, respectively; P < 0.001). The EBP Pak was comparable to the EBP Jar in terms of reduction in acne lesions, Physician's Global Acne Severity scores, and end-of-treatment patient evaluations of global improvement. No serious drug-related adverse events were reported. Conclusions: Results of this 8-week trial demonstrate that the single-use combination package of EBP is well tolerated, effective, and comparable to the original formulation for the treatment of acne vulgaris in this selected patient population." @default.
• W2003948381 created "2016-06-24" @default.
• W2003948381 creator A5017289880 @default.
• W2003948381 creator A5022350422 @default.
• W2003948381 creator A5032031090 @default.
• W2003948381 creator A5070307573 @default.
• W2003948381 creator A5075725987 @default.
• W2003948381 creator A5087549040 @default.
• W2003948381 date "2002-05-01" @default.
• W2003948381 modified "2023-10-03" @default.
• W2003948381 title "A randomized, parallel, vehicle-controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris" @default.
• W2003948381 cites W1964675629 @default.
• W2003948381 cites W1969502034 @default.
• W2003948381 cites W1981279298 @default.
• W2003948381 cites W2001025975 @default.
• W2003948381 cites W2075642873 @default.
• W2003948381 cites W2095218865 @default.
• W2003948381 cites W2147689216 @default.
• W2003948381 cites W2150310143 @default.
• W2003948381 cites W2155353386 @default.
• W2003948381 cites W4301514587 @default.
• W2003948381 cites W4323646420 @default.
• W2003948381 doi "https://doi.org/10.1016/s0149-2918(02)85151-7" @default.
• W2003948381 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12075945" @default.
• W2003948381 hasPublicationYear "2002" @default.
• W2003948381 type Work @default.
• W2003948381 sameAs 2003948381 @default.
• W2003948381 citedByCount "15" @default.
• W2003948381 countsByYear W20039483812012 @default.
• W2003948381 countsByYear W20039483812014 @default.
• W2003948381 countsByYear W20039483812019 @default.
• W2003948381 countsByYear W20039483812020 @default.
• W2003948381 crossrefType "journal-article" @default.
• W2003948381 hasAuthorship W2003948381A5017289880 @default.
• W2003948381 hasAuthorship W2003948381A5022350422 @default.
• W2003948381 hasAuthorship W2003948381A5032031090 @default.
• W2003948381 hasAuthorship W2003948381A5070307573 @default.
• W2003948381 hasAuthorship W2003948381A5075725987 @default.
• W2003948381 hasAuthorship W2003948381A5087549040 @default.
• W2003948381 hasConcept C126322002 @default.
• W2003948381 hasConcept C141071460 @default.
• W2003948381 hasConcept C16005928 @default.
• W2003948381 hasConcept C168563851 @default.
• W2003948381 hasConcept C178790620 @default.
• W2003948381 hasConcept C185592680 @default.
• W2003948381 hasConcept C197934379 @default.
• W2003948381 hasConcept C203092338 @default.
• W2003948381 hasConcept C204243189 @default.
• W2003948381 hasConcept C2777140388 @default.
• W2003948381 hasConcept C2777673923 @default.
• W2003948381 hasConcept C2778375690 @default.
• W2003948381 hasConcept C2778885487 @default.
• W2003948381 hasConcept C2779384505 @default.
• W2003948381 hasConcept C2780206985 @default.
• W2003948381 hasConcept C2780400711 @default.
• W2003948381 hasConcept C2781156865 @default.
• W2003948381 hasConcept C2781464078 @default.
• W2003948381 hasConcept C2908647359 @default.
• W2003948381 hasConcept C44228677 @default.
• W2003948381 hasConcept C500558357 @default.
• W2003948381 hasConcept C501593827 @default.
• W2003948381 hasConcept C521977710 @default.
• W2003948381 hasConcept C71924100 @default.
• W2003948381 hasConcept C86803240 @default.
• W2003948381 hasConcept C89423630 @default.
• W2003948381 hasConcept C99454951 @default.
• W2003948381 hasConceptScore W2003948381C126322002 @default.
• W2003948381 hasConceptScore W2003948381C141071460 @default.
• W2003948381 hasConceptScore W2003948381C16005928 @default.
• W2003948381 hasConceptScore W2003948381C168563851 @default.
• W2003948381 hasConceptScore W2003948381C178790620 @default.
• W2003948381 hasConceptScore W2003948381C185592680 @default.
• W2003948381 hasConceptScore W2003948381C197934379 @default.
• W2003948381 hasConceptScore W2003948381C203092338 @default.
• W2003948381 hasConceptScore W2003948381C204243189 @default.
• W2003948381 hasConceptScore W2003948381C2777140388 @default.
• W2003948381 hasConceptScore W2003948381C2777673923 @default.
• W2003948381 hasConceptScore W2003948381C2778375690 @default.
• W2003948381 hasConceptScore W2003948381C2778885487 @default.
• W2003948381 hasConceptScore W2003948381C2779384505 @default.
• W2003948381 hasConceptScore W2003948381C2780206985 @default.
• W2003948381 hasConceptScore W2003948381C2780400711 @default.
• W2003948381 hasConceptScore W2003948381C2781156865 @default.
• W2003948381 hasConceptScore W2003948381C2781464078 @default.
• W2003948381 hasConceptScore W2003948381C2908647359 @default.
• W2003948381 hasConceptScore W2003948381C44228677 @default.
• W2003948381 hasConceptScore W2003948381C500558357 @default.
• W2003948381 hasConceptScore W2003948381C501593827 @default.
• W2003948381 hasConceptScore W2003948381C521977710 @default.
• W2003948381 hasConceptScore W2003948381C71924100 @default.
• W2003948381 hasConceptScore W2003948381C86803240 @default.
• W2003948381 hasConceptScore W2003948381C89423630 @default.
• W2003948381 hasConceptScore W2003948381C99454951 @default.
• W2003948381 hasIssue "5" @default.
• W2003948381 hasLocation W20039483811 @default.
• W2003948381 hasLocation W20039483812 @default.
• W2003948381 hasOpenAccess W2003948381 @default.
• W2003948381 hasPrimaryLocation W20039483811 @default.

• next